

**Date:** 17<sup>th</sup> May 2026

To,  
Listing Compliance Department,  
**National Stock Exchange of India Limited,**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra East, Mumbai-400051

**NSE Symbol: Madhavbaug**

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

---

Pursuant to the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a copy of the Investor Presentation on Audited Financial Results of the Company for the financial year ended 31<sup>st</sup> March 2026.

We would request you to take the above intimation on records.

For, **Vaidya Sane Ayurved Laboratories Limited**

*Sapna Vaishnav*

**Company Secretary and Compliance Officer**

---

**VAIDYA SANE AYURVED LABORATORIES LIMITED.**

---

**Registered Office Address:**

Fl. 5 1047, Shriram Bhawan, Shukrawar Peth, Pune 411002,  
Maharashtra, India.

CIN: L73100PN1999PLC013509

**Corporate office Address:**

1702 to 1706, 17th Floor, Mahavir Business Park, Opp. Eternity Mall,  
Teen Haath Naka, LBS Road, Thane (W) - 400604. Maharashtra, India.

Tel: 022-41235315/16

[www.madhavbaug.org](http://www.madhavbaug.org)



## Vaidya Sane Ayurved Laboratories Limited

Investor  
Presentation






# Disclaimer



*This presentation has been prepared by Vaidya Sane Ayurved Laboratories Limited (the “Company”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.*

*This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.*

*Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.*





# Table of contents



**Company Overview**



**Business Overview**



**Industry Overview**



**Financial Highlights**



**Way Ahead**





# COMPANY ———— ————— OVERVIEW



# About Us

## Among leading chains of Cardiac care clinics & Hospitals

- Unique medical service institution – focus on **Traditional Medicine**
- Strives to reduce India's disease burden of **Cardiac disease, Diabetes, Hypertension and Obesity**

## Madhavbaug has

- **320\*** Clinics Across India
- Rural reach of **46+ OPDs and Mini Clinics**
- **450+** Ayurveda Physicians
- Treated Over **10 Lakhs** Patients Successfully
- **83 manuscript and 500** Research Paper Publications
- **200+** Awards & Recognitions
- Tie up with more than 9 TPA and 12 Insurance Companies



## State of Art Fully Equipped Hospitals

- Madhavbaug Hospital Khopoli (**NABH Accredited**)
- Madhavbaug Hospital Nagpur
- Madhavbaug Vizag Hospital

## Treatments

- Heart Disease Reversal
- Diabetes Reversal
- BP Management
- Obesity Management
- Knee Pain Relief Camp

## Our Treatment Philosophy

- Holistic Non-invasive Treatments
- Advanced Research & Technology
- Patient-Centric Care

## Vision

*“To make evidence-based Ayurveda the first line for lifestyle disease reversal in India and beyond.”*



 Quality


 Access

 Affordability

 Outcomes

## Mission 2028 / 2030

Bring **5 Crore** people under care via:

 **1,000** Clinics Nationwide

 **10** Operational Hospitals

# Company Structure

01

## F-Health Accelerators Pvt. Ltd. (80% Holding)

- Focus on start-ups that work in the areas of D2C, home healthcare, telemedicine, patient centric innovations, Med-tech and digital therapeutics
- Made primary investment in SNA Milk and Milk Products Private Limited and Justkare Technologies Private Limited

02

## Easy Ayurveda Pvt. Ltd. (15% Holding)

- Shareholding Agreement with Dr. Janardhana V Hebbar
- Help to spread and disseminate awareness, knowledge, education, training about the Ayurveda treatments, therapies and products in world and provide the common forum of interaction, training courses and special programmes to impart training, education in Ayurveda

03

## Aaharshashtra Foodz Pvt. Ltd. (100% Holding)

- Incorporated a Company with Ms. Ritika Kandhar - 14 years of marketing experience with degree in MBA from IIM Shillong and B Pharma from IIT BHU
- Years of research on grains, nutrition, and customer preferences led to the creation of FoodRx
- FoodRx - Designed to support balanced nutrition, better digestion, and overall health

04

## Joint Healing Services Pvt. Ltd. (0.5% Holding)

- Joint pain and Muscle pain related Healthcare Exercise platform, workshop, camps and other related activities
- Joint Healers is a pain management system with a holistic approach towards a pain free life and focuses on improving quality of it. This is the combination of modern and traditional way of treatment

05

## Dynamic Remedies Pvt. Ltd. (100% Holding)


- Manufacturing of Ayurvedic Medicines
- Dynamic has diverse medicine and product portfolio and it is one of the top suppliers of Company's Ayurvedic medicines, Dynamic shares major share in Company's Medicines and Product Portfolio

06


## UV Ayurgen Pharma Pvt. Ltd. (100% Holding)

- Manufacturing of Ayurvedic medicines and Nutra Products
- UV Ayurgen has diverse medicine and diet product portfolio and it is one of the key suppliers of Company's Ayurvedic medicines and Diet products

# Madhavbaug's 360° Care Ecosystem



# Journey so far



# Experienced Management Team



**Dr. Rohit Madhav Sane**  
Chairman & Managing Director

Founder | MBBS (Medicine and Surgery)  
| Preventive cardiology specialist |  
20+ years experience



**Dr. Vidyut Bipin Garg**  
Whole Time Director

BAMS from Ayurved Mahavidyalay |  
PGDM DLP (2 YRS) in Healthcare | 20+  
years experience as Chief Administrative  
Officer



**Dr. Gurudatta Amin**  
Chief Medical Officer

BAMS, MD (Samhita, Siddhant), PGDEMS  
and Certified Black belt in Six Sigma  
| 19+ years experience as Chief Medical  
Officer



**Mr. Narendra Pawar**  
Chief Financial Officer

MBA (Finance) from ICAI University,  
Hyderabad | 30+ years experience in  
Accounting, Finance and Taxation



**Ms. Sapna Vaishnav**  
Company Secretary & Compliance Officer

Associate Member of ICSI and Law Graduate  
| 7+ years experience as a Chief Compliance  
Officer



# Key Strengths



Unique combination of modern healing methods and ancient natural practices

Effective, Non- Invasive & Affordable Treatments to improve overall health of society

Innovation & Technology platform helps core medical team to interact with on ground team of doctors & therapists to increase efficiency

Powerful Tool - Madhavbaug POWER MAP aims to provide in depth medical analysis of Patients current health status



Experienced Leadership with able & well-trained team led by Dr. Rohit Madhav Sane

State of the art in-house manufacturing facilities leads to greater economies of scale, stricter quality control and expand our product portfolio

Strong Efficient Clinic Management Systems to gather vital information for getting quick results

MIB Pulse App – Chat based Technical solution to connect patients with team of doctors for effective consultations & solutions



# Business OVERVIEW



# Business Model Three Pillars



## Clinics

- 320+ company-owned & franchise clinics
- ~77% revenue share from franchise network
- Contributes 61.95% of total service revenue



## Hospitals

- 4 facilities with 134+ beds operational
- High-ticket disease reversal cases
- ₹4-5 lakh average revenue per bed/month



## Products

- Ayurvedic medicines & standardized diet kits
- In-house manufacturing for quality control
- Forms 38.05% of enterprise revenue in FY26





**FY26 Enterprise Revenue**  
₹ 196.91 Cr

**Business Model**  
(Clinics 84.58% | Hospitals 15.42%)

**Clinics Revenue : Rs. 166.55 Crs**  
(Products 38.05% | Services 61.95%)

# Three Pillars of Treatment Protocol



Progress tracked digitally via MIB Pulse app



## Heart Disease Reversal

- Cardioprotective Therapy
- Ischemic Reversal Program
- CAD Management
- Heart Failure Reversal Therapy



## Diabetes Reversal

- Comprehensive Diabetic Care Program
- Diabetes Complication Management Program (Pre-Failure)
- Diabetes Complication Management Program (Pre-Ischaemia)



## Blood Pressure Management

- Blood Pressure Management Program
- Blood Pressure Complication Management Program (Pre-Failure)
- Blood Pressure Complication Management Program (Pre-Ischaemia)




## Obesity Management


- Obesity Management Program
- Helps reduce body weight - lowers risk of heart disease, diabetes, cholesterol, and high blood pressure

# Revenue Streams & Unit Economics

## Business Model (FY26)



## Clinic Revenue Model (FY26)



**Clinic ARPU**

**₹10-13K**

per new patient  
(preventive care)

**Disease Reversal**

**₹50-60K**

per patient annually  
(high-value pivot)

**Hospital Revenue**

**₹4-5 Lakh**

average revenue  
per bed/month

**Franchise Share**

**~40%**

revenue share  
accruing to company

# Hospital Network – Capacity & Locations



**Khopoli**

**45**


BEDS

Cashless/CGHS Empaneled

1st Hospital in 2006

Fully operational primary flagship facility

Khopoli Hospital (Revenue in Rs. Cr)



**Kondhali**

**30**


BEDS

Empanelment in Progress

2<sup>nd</sup> Hospital in 2012

Key central India hub with upcoming expansion

Kondhali Hospital (Revenue in Rs. Cr)



**Vizag**

**24**


BEDS

Empanelment in Progress

3<sup>rd</sup> Hospital in 2023

Expanding regional footprint in southern markets

Vizag Hospital (Revenue in Rs. Cr)



**Vadodara**

**35**


BEDS

Empanelment in Progress

4<sup>th</sup> Hospital in 2025

Newest strategic facility addressing western region

Vadodara Hospital (Revenue in Rs. Cr)



# Hospital Capabilities & Services



## Diagnostics

- ✓ ECG
- ✓ 2D Echo
- ✓ Stress Test
- ✓ CT Angiography
- ✓ Pathology Lab
- ✓ Ambulatory Monitoring



## Clinical Services

- ✓ HFRT Program
- ✓ IRP Program
- ✓ CDC Program
- ✓ Panchakarma Therapies
- ✓ Inpatient Care
- ✓ Day - Care Procedures



## Support Services

- ✓ Dietetics
- ✓ In-house Pharmacy
- ✓ Remote Monitoring
- ✓ Standardized SOPs
- ✓ Patient Education
- ✓ Insurance Facilitation



**134+**  
Total Beds

**Scaling to 250-300 beds in 12-15 months**

With a strategic long-term vision of establishing **1,000 beds** in 4-5 years.

# Patient Journey – 12 Month Protocol



## Phase 1: Aggressive

MONTHS 1 - 3

- ✓ Detailed diagnosis & profiling
- ✓ Initial Panchakarma procedures
- ✓ Aggressive medicine titration
- ✓ Strict standardized diet protocol
- ✓ Intensive weekly monitoring

## Phase 2: Conservative

MONTHS 4 - 12

- ✓ Maintenance Panchakarma
- ✓ Physiological stabilization
- ✓ Long-term lifestyle integration
- ✓ Structured monthly follow-ups
- ✓ Digital outcome tracking
- ✓ Sustained disease reversal



Measurable improvements tracked digitally via MIB  
Pulse application

**12-Mo**

Total Duration

**3-Mo**

Aggressive Phase

**9-Mo**

Conservative Phase

# Multidisciplinary Cardiac Care Clinics



# Malaysia – International Expansion via Maxura JV

First international footprint with strategic 70:30 partnership

**Madhavbaug**

**70%**

Clinical IP & Research  
Standardized Protocols  
Brand Equity & Trust  
Physician Training



**Profit-Sharing JV**  
(70:30)

**Maxura Healthcare**

**30%**

Local Operations Setup  
Regulatory Approvals  
Regional Marketing  
Clinic Infrastructure

## Asset-Light Entry

Minimal capex requirement from Madhavbaug

## Proven Protocols

Replicable Ayurvedic IP ready for international markets

## Growing NCD Market

Tapping into rising Malaysia and ASEAN healthcare demand

## Scalable Template

Foundation for broader global expansion strategy

# Urja Neuro Care – Strategic New Vertical

Expanding therapeutic portfolio into neurological disorders



## Urja Neuro Care

**₹1.8 Cr** Investment

Neurological Disorders

Ayurvedic Approach

Specialty Care

Pilot Launch FY26



### Diversification

Strategic expansion of therapeutic focus beyond existing cardiac and diabetes leadership.



### High-Need Segment

Targeting unaddressed demand in Parkinson's, Alzheimer's, and paralysis rehabilitation.



### Asset-Light Investment


Prudent capital allocation with an initial ₹1.8 Cr seed deployment to pilot the program.




Builds on Madhavbaug's clinical research foundation and Ayurvedic IP for neurological care delivery

# Multidisciplinary Cardiac Care Clinics


**No. of Clinics (Ownershipwise)**




**Average Revenue per Clinic (Rs. in Lacs)**




**Clinic Enterprise Revenue (In Rs. Lacs)**




**No. of Patient - Total Footfall**




**Enterprise Revenue (Rs. Cr)**




**Total Product Revenue per Clinic (Rs. In Lacs)**



**Total Services Revenue per Clinic (Rs. in Lacs)**



**No. of Patient – New Patient Footfall**



\*\*Enterprise Collection includes standalone revenue of the company as well as Collection made by Franchisee Clinics  
All above numbers are Enterprise Revenue

# Subsidiaries – In-house Manufacturing

## **Dynamic Remedies Pvt Ltd**

- ✓ Ayurvedic formulations and nutraceuticals
- ✓ Standardized diet kits production
- ✓ GMP-aligned manufacturing facility
- ✓ Supply assurance for clinic & hospital network

## **UV Ayurgen Pharma Pvt Ltd**

- ✓ Standardized, metal-free Ayurvedic medicines
- ✓ Stringent quality control across formulations
- ✓ R&D pipeline for new clinical protocols
- ✓ Margin enhancement via vertical integration


 **Quality Control**

 **Supply Assurance**

 **Cost Efficiency**

 **Faster R&D Cycle**

# Subsidiaries – In-house Manufacturing



# 320+

## Clinics Nationwide

Across 14 States & Union Territories

Maharashtra	247
Gujarat	23
Karnataka	22
Madhya Pradesh	11
Uttar Pradesh	11
Delhi-NCR	6

 **4 Operational Hospitals**

134 Total Beds

**Khopoli:** 45 Beds | **Vadodara:** 35 Beds

**Vizag:** 24 Beds | **Kondhali (Nagpur):** 30 Beds

# Empanelment with Insurance Companies & TPA'S

## Insurance Companies




## Third Party Administrators (TPA)



More than 30 Insurance companies empaneled with above Third Party Administrators (TPA) each

# Digital Ecosystem - Mib Pulse App

MIB Pulse App (+100K Downloads)



- It's a free app which anyone can use from anywhere in case of Medical assistance
- App gives you full past history of your health



## Medical Assistance

- ✓ Connected Medical Assistance of Doctors to give patients appropriate solution through live chat and vitals monitoring



## Diet & Exercise Monitoring

- ✓ Diet and exercise monitoring to get maximum benefits out of Healthy lifestyle management



## Staying Fit

- ✓ Daily Health coaching through video based Diet and Exercise sessions to maintain healthy life & improve lifestyle



## Health Monitoring

- ✓ InApp chat based close Health Monitoring through Vital parameters



## Expert Medicine management support

- ✓ Medicine reminders, Realtime Medicine tapering advise of connected Doctors

# Digital Ecosystem – Power Map

- Medical analytics service built for Madhavbaug Doctors to help them reverse Chronic cardiac disease of their patients effectively -
- Union Minister for Road Transport and Highways Nitin Gadkari inaugurated Madhavbaug's Power MAP on 15<sup>th</sup> January 2022



## Critical Care



## Diet Management



## Close Medical Monitoring



## Medicine Management



## Medical Intelligence

- ✓ Disease Reversal Score
- ✓ Medicine Tapering score
- ✓ Complication Prediction (In development)
- ✓ E-Library (In development)



## Health Coach Support



## Super-Consultant support




## Medical Services Management




## Health Timeline



## Lifestyle Management



# Research based Disease reversal Diet Kits





# Industry OVERVIEW



# India's Non - Communicable Disease (NCD) Challenges

**68% of all death in India caused by Non – Communicable diseases**

## Diabetes

- Roughly **77 million** Diabetes patients in India – Second Highest in the World
- **Every 2 minutes**, someone in India dies from diabetes or its complications — over **2.5 lakh deaths per year. (WHO and Global Burden of Disease reports)**



India estimated to have **44 million** undiagnosed Diabetes patients

## Obesity

- India has **136 million** obese people - **National Family Health Survey (NFHS-5)**
- Obesity in children under age of 5 - doubled in state of Maharashtra



By 2030 India to have **27.8%** of world's obese people

## Hypertension

- India has **207 million** people with Hypertension
- **1.63 million** Indians die of Hypertension p.a (**Journal of the American Medical Association**)



Prevalence of Hypertension increased from **11.3% to 25.3%**

## Cardiovascular

- Estimated **54.5 million** CVD patients in India (**Global Burden of Disease (GBD) Study**)
- **2.6 million** Indians die of CVD every year



**CVD** responsible for **43%** of NCD death and **27%** of all death

**India staring at Heart Disease Epidemic - current Cardiac Care ecosystem with focus mainly on surgical interventions will not be able to handle this load single-handedly**

**Need of hour - Prevention & Rehabilitation focused Cardiac Care System - complements current systems**



**Result Oriented**



**Clinically Researched**



**Scalable**



**Accessible**




**Easy to Adhere**

**Madhavbaug has designed & implemented such Diabetes & Cardiac care systems**


# Higher Stress increasing Diseased Population




Middle Class Population ( In million)



Working Age Population of India (in million)



Share of Non-communicable diseases – Causes of death, India, 2000-25



# Re-emergence of Traditional Medical Care

## Market size and services offered

- Indian Ayurvedic Industry expected to reach US\$ 9 billion by 2022 - Ayurveda medicines - > 90% plant based formulations
- Broadened offerings - services on diet and nutrition, yoga, herbal medicine, humour therapy and spa

## Leading brands and players

- Many big players such as Apollo, VLCC and Manipal Group setting up wellness centers across India with traditional healthcare remedies

## Developing infrastructure

- In July 2021, Union Cabinet approved continuation of National Ayush Mission, responsible for development of traditional medicines in India, as centrally sponsored scheme until 2026



## Notable trends

- Traditional medical sector developing Traditional Knowledge Digital Library to prevent companies from claiming patents on such remedies
- Growing interest from PE firms in traditional Indian healthcare sector
- Center revamping existing 1.5 lakh wellness health centers across country

## Recent Developments

- The Ministry of Ayush was allocated Rs 3,712.49 crore in 2024-25 Interim Budget. This is a 23.74% increase from the previous year's budget allocation of Rs 3,000 crore
- WHO's Launch of Ayurveda Research Institutions

## IRDAI announced new regulations that insurance providers to offer Ayush coverage in Health Insurance

- Insurers must offer board-approved plans that treat AYUSH treatments similarly to other medical treatments
- Insurers must include quality standards and procedures for enrolling AYUSH hospitals and day care centers into their network for cashless treatment

**India Emerging as Global Wellness & Ayurveda Hub - Ayurveda at Top of Immunity Boosting Shelves**



# Financial Highlights



# Management Comments



**Commenting on H2 & FY26 results,  
Dr. Rohit Sane,  
Chairman & Managing Director,  
Vaidya Sane Ayurved Laboratories  
Limited said:**

*"FY26 has been a year of strong business momentum and strategic expansion for Vaidya Sane Ayurved Laboratories. During the year, we achieved a healthy revenue growth of 18.9% to ₹106.9 crore, driven by sustained patient additions, growing acceptance of Ayurvedic healthcare solutions, and continued strengthening of our clinical network. Our gross margins remained robust at over 82%, reflecting the strength of our integrated healthcare model and operational efficiencies across the business.*

*During H2 FY26, revenue grew by 18.4% year-on-year to ₹57.0 crore. While we witnessed healthy growth in business volumes, profitability during the period was impacted by higher investments towards expansion, branding, technology initiatives, and operational strengthening to support our long-term growth strategy. Other expenses increased as we continued to invest in enhancing patient engagement, expanding our reach, and building a stronger healthcare ecosystem.*

*During the year, we also took a strategic step towards strengthening our healthcare platform with the proposed acquisition of Parasnath Healthcare (OPC) Private Limited. This acquisition aligns with our long-term vision of expanding our healthcare capabilities, enhancing service offerings, and strengthening our presence in the integrated healthcare ecosystem. We believe this proposed transaction will create operational synergies, broaden our reach, and support sustainable growth going forward, subject to completion of definitive agreements and applicable regulatory approvals.*

*The demand environment for preventive and chronic care management through Ayurveda continues to remain encouraging, supported by increasing health awareness and preference for holistic treatment solutions. Going forward, we remain focused on expanding our presence, improving operational efficiencies, leveraging technology-driven patient care, and strengthening our brand positioning across key markets. We believe our integrated approach, strong medical expertise, and patient-centric healthcare model will continue to drive sustainable growth in the coming years.*

*By 2030, our goal is to establish 1,000 clinics, 10 hospitals, and 5,000 outpatient departments, especially in rural India. Through our Institute of Preventive Cardiology, we are also committed to training 10,000 physicians to advance our leadership in preventive healthcare.*

*We remain committed to delivering world-class patient care through medical excellence, innovation, and a dedicated team of doctors and staff, while ensuring a safe environment for all.*

# Proposed Acquisition : Parasnath Healthcare (OPC) Pvt. Ltd.

## Expanding Healthcare Capabilities & Strengthening Market Presence

### Transaction Snapshot

Key deal metrics and terms

Acquisition Cost  
**₹6.0 Crores**

Stake Acquired  
**100%**

Shares  
**10,000 equity shares**

Face Value  
**₹10/- each**

**Subject to regulatory approvals**

### Payment Terms

Cash consideration of ₹6 crores, payable upon completion of closing conditions as specified in the Definitive Acquisition Agreement

### Strategic Rationale

Business expansion & synergies

- ✓ **Strategic Business Expansion:** Expands healthcare capabilities into specialized pain management and clinic operations
- ✓ **Consolidation of Franchisee Operations:** Strengthens presence in integrated healthcare ecosystem
- ✓ **Enhanced Service Offerings:** Adds specialized knee pain and clinic-related services
- ✓ **Operational Synergies:** Creates cost efficiencies and broadens market reach

### Target Profile

Parasnath Healthcare overview

Company Type  
Active Unlisted OPC

Incorporation Date  
3 Feb 2022

CIN Number  
U85191PN2022OPC208212


Registered Office  
Sangli, Maharashtra

### Specialization


Public website focus: non-surgical Ayurvedic specialty care for knee pain, spine disorders, gout, rheumatism, frozen shoulder, tennis elbow, and related pain management

# Consolidated Half Yearly – Financial Highlights


### Enterprise Collection (Rs. Cr)




### Revenue (Rs. Cr)



### EBITDA\* (Rs. Cr)



### PAT (Rs. Cr)



# Consolidated Financial Highlights – Half Yearly

Rs. Crore	H2 FY26	H2 FY25	Y-o-Y (%)	H1 FY26
Income from Operations	56.96	48.12		49.94
Other Operating Income	0.00	0.00		0.00
<b>Total Income</b>	<b>56.96</b>	<b>48.12</b>	<b>18.37%</b>	<b>49.94</b>
Raw Materials	10.64	9.86		<b>8.29</b>
Employee Cost	8.58	8.65		9.59
Other Expenses	30.95	21.05		23.44
<b>Total Expenditure</b>	<b>50.17</b>	<b>39.56</b>	<b>26.81%</b>	<b>41.32</b>
<b>EBITDA (Excluding other income)</b>	<b>6.80</b>	<b>8.56</b>	<b>(20.61%)</b>	<b>8.62</b>
<b>EBIDTA Margin%</b>	<b>11.93%</b>	<b>17.79%</b>	<b>(586 bps)</b>	<b>17.26%</b>
Other Income	1.42	0.95		0.95
Depreciation	3.13	2.39		3.00
Interest	0.75	0.77		0.10
Exceptional Item (Gain) / Loss	0.00	1.20		0.00
<b>Profit Before Tax</b>	<b>4.34</b>	<b>5.15</b>	<b>(15.70%)</b>	<b>6.47</b>
Tax	0.18	1.76		1.63
<b>Profit After Tax</b>	<b>4.15</b>	<b>3.38</b>	<b>22.77%</b>	<b>4.84</b>
<b>PAT Margin %</b>	<b>7.29%</b>	<b>7.03%</b>	<b>26 bps</b>	<b>9.68%</b>
<b>Basic EPS in Rs.</b>	<b>3.95</b>	<b>3.19</b>	<b>23.82%</b>	<b>4.56</b>

- Revenue from operations for H2 FY26 is 56.96 Crs as against Rs. 48.12 Crs in H2 FY25, YoY Increase of 18.37% - led by higher patient engagement, improved therapy adoption, and robust growth in wellness product sales
- EBITDA (excluding Other Income) - Rs. 6.80 Crs in H2 FY26 as against Rs. 8.56 Crs in H2 FY25, decrease of 20.61% due to sharp increased in other expenses.


# Consolidated Financial Highlights –Yearly

Rs. Crore	FY26	FY25	Y-o-Y (%)
Income from Operations	106.91	89.92	
Other Operating Income	0.00	0.00	
<b>Total Income</b>	<b>106.91</b>	<b>89.92</b>	<b>18.89%</b>
Raw Materials	18.93	19.07	
Employee Cost	18.17	19.06	
Other Expenses	54.39	37.47	
<b>Total Expenditure</b>	<b>91.49</b>	<b>75.60</b>	<b>21.02%</b>
<b>EBITDA (Excluding other income)</b>	<b>15.42</b>	<b>14.32</b>	<b>7.63%</b>
<b>EBIDTA Margin%</b>	<b>14.42%</b>	<b>15.93%</b>	<b>(151 bps)</b>
Other Income	2.37	1.78	
Depreciation	6.13	4.16	
Interest	0.85	0.85	
Exceptional Item (Gain) / Loss	0.00	1.20	
<b>Profit Before Tax</b>	<b>10.81</b>	<b>9.90</b>	<b>9.16%</b>
Tax	1.82	2.74	
<b>Profit After Tax</b>	<b>8.99</b>	<b>7.15</b>	<b>25.66%</b>
<b>PAT Margin %</b>	<b>8.41%</b>	<b>7.96%</b>	<b>45 bps</b>
<b>Basic EPS in Rs.</b>	<b>8.51</b>	<b>6.78</b>	<b>25.52%</b>


- Revenue from operations for FY26 is 106.91 Crs as against Rs. 89.92 Crs in FY25, YoY Increase of 18.89% - driven by sustained patient additions, growing acceptance of Ayurvedic healthcare solutions, and continued strengthening of our clinical network
- EBITDA (excluding Other Income) - Rs. 15.42 Crs in FY26 as against Rs. 14.32 Crs in H2 FY25 increase of 7.63% due to revenue growth, improvement in gross margins and cost control on the employee front

# Annual Financial Highlights


### Enterprise Collection (Rs. Cr)




### Revenue (Rs. Cr)



### EBITDA\* (Rs. Cr)



### PAT (Rs. Cr)



\* Excluding other income


# Balance Sheet as on 31<sup>st</sup> March 2026

Rs. Crore	As on 31 <sup>st</sup> Mar' 26	As on 31 <sup>st</sup> Mar' 25
<b>Shareholder's Funds</b>	<b>71.68</b>	<b>62.55</b>
Share capital	10.52	10.52
Other Equity	61.16	52.03
Money received against share warrants	0.00	0.00
Share Application Pending Allotment	15.76	0.00
Minority Interest	0.00	0.00
<b>Non-current liabilities</b>	<b>5.96</b>	<b>4.42</b>
<b>Financial Liabilities</b>		
Borrowing	2.59	1.48
Provisions	1.94	1.64
Deferred Tax Liabilities (Net)	0.00	0.05
Other Non-Current Liabilities	1.44	1.25
<b>Current liabilities</b>	<b>11.11</b>	<b>11.98</b>
<b>Financial Liabilities</b>		
Borrowing	0.00	0.00
Trade Payable	6.57	6.52
Other Current Liabilities	1.78	1.86
Provisions	2.76	3.60
<b>Total Equities &amp; Liabilities</b>	<b>104.51</b>	<b>78.96</b>


Rs. Crore	As on 31 <sup>st</sup> Mar' 26	As on 31 <sup>st</sup> Mar' 25
<b>Non-current assets</b>	<b>60.20</b>	<b>48.32</b>
Property, Plant & Equipment	21.94	21.45
Intangible assets	12.59	12.21
Capital WIP	2.14	1.26
Deferred Tax Assets	0.15	0.00
Long term loans and advances	2.96	3.09
Non Current Investment	17.26	7.97
Other Non Current Assets	3.16	2.34
<b>Current assets</b>	<b>44.31</b>	<b>30.64</b>
current investment	22.63	13.34
Inventories	3.65	3.76
<b>Financial Assets</b>		
Trade receivables	10.23	7.47
Cash & Cash equivalent	0.44	2.36
Loans	7.37	3.67
Other Current Assets	0.00	0.05
<b>Total Assets</b>	<b>104.51</b>	<b>78.96</b>

# Key Balance Sheet Ratios


RoE(%)



RoA(%)



RoCE(%)



\* IPO in FY22 to raise Rs. 20.23 crs


RoE = Net Profit/Net Worth | RoA = Net Profit/Average Total Assets / RoCE = EBIT/(Shareholders Fund + Total Debt-non current investments)



**Way**

**Ahead**







For further information, please contact:



**Mr. Amit Sharma / Mr. Rupesh Rege**  
**AdfactorsPR Pvt. Ltd.**

Tel: +91 98677 26686 / +91 9594918891

Email: [amit.sharma@adfactorspr.com](mailto:amit.sharma@adfactorspr.com)

[rupesh.rege@adfactorspr.com](mailto:rupesh.rege@adfactorspr.com)

Website : [www.adfactorspr.com](http://www.adfactorspr.com)

**Thank You**

